New 20-Minute Portable PCR Test Detects Tuberculosis From Tongue Swabs in the Field
Northwestern University researchers have developed a portable, battery-operated PCR system that detects tuberculosis from a simple tongue swab in 20 minutes. The device eliminates the need for laboratory infrastructure and difficult-to-produce sputum samples, enabling same-day diagnosis and treatment in remote clinics.
By Maya Khalil
Share this story
The standard assumption in global health has long been that accurate molecular testing for tuberculosis requires deep-lung sputum and a climate-controlled laboratory. A new portable device challenges that constraint, delivering gold-standard polymerase chain reaction results from a simple tongue swab in 20 minutes.[1][5]
Engineers at Northwestern University have adapted their DASH Rapid PCR System to detect Mycobacterium tuberculosis directly in the field. The findings, published November 12, 2026, in Open Forum Infectious Diseases, demonstrate that the battery-operated unit matches the accuracy of established laboratory diagnostics.[1][3]
The World Health Organization reported that tuberculosis killed 1.23 million people globally in 2024, cementing its status as the world's deadliest infectious disease. The hardest-hit communities often reside in impoverished or remote areas where consistent electricity and specialized medical facilities are entirely absent.[2]
"Diagnosis is the weakest link in tuberculosis care," said Sally McFall, a research professor of biomedical engineering at Northwestern and the study's corresponding author. "Bacterial culture is the gold standard. It has high sensitivity, but the time-to-result is lengthy, and it is technically challenging and prone to contamination."[2]
By shrinking the diagnostic window from days to just 20 minutes, the DASH system allows healthcare workers to test and treat a patient during a single clinic visit. This immediate turnaround prevents infected individuals from returning to their communities and inadvertently spreading the airborne bacteria.[1][4]
The rapid intervention is critical for breaking the chain of transmission in densely populated environments. Tuberculosis spreads through infected air droplets that can linger in poorly ventilated spaces for hours, posing a severe risk to both healthcare workers and household contacts.[2][5]
Bypassing the sputum barrier
Traditional tuberculosis diagnostics rely heavily on sputum, the thick mucus expelled from the deep lungs and airways. While sputum carries a high bacterial load that makes detection easier, acquiring a viable sample remains a persistent and frustrating clinical hurdle.[2][5]
"Sputum is the preferred specimen for tuberculosis diagnosis, but up to one-third of patients cannot produce sputum and thus cannot be diagnosed," McFall said. The inability to produce a sample disproportionately affects young children, the elderly, and patients in the early stages of the disease.[1]
To bypass this physical limitation, the Northwestern team optimized the DASH system to process tongue swabs alongside traditional sputum samples. The non-invasive swab simply sweeps the surface of the tongue, requiring no deep coughing, aerosol-generating procedures, or specialized collection protocols.[1][3]
In a clinical study of 110 tongue swab specimens collected from symptomatic patients in South Africa, the rapid test demonstrated a sensitivity of 91 percent. It correctly identified every true negative case in the cohort, achieving a flawless 100 percent specificity rate.[2][3]
The researchers found that the DASH system's performance matched that of Cepheid's Xpert MTB/RIF Ultra test, which is currently the most widely adopted molecular diagnostic tool for the disease. The new device successfully detected as few as 2.5 bacterial cells per swab.[2][3]
The ability to achieve such high sensitivity from a tongue swab represents a major technical achievement. Mycobacterium tuberculosis is notoriously resistant to conventional bacterial lysis techniques, forcing the engineering team to evaluate multiple pre-cartridge lysing methods before selecting a highly effective sonication approach.[3]
Engineering for extreme environments
Transporting sensitive molecular diagnostics into rural clinics typically requires an unbroken cold chain, as standard PCR reagents degrade quickly at room temperature. The Northwestern engineers bypassed this logistical nightmare by developing highly resilient, self-contained testing cartridges.[1][2]
The DASH cartridges remain completely stable at 45 degrees Celsius for up to a full year. This thermal stability allows health ministries to stockpile and distribute the tests via standard supply routes, without relying on refrigeration or air conditioning.[2][3]
The hardware itself is specifically designed for austere clinical environments. The compact device weighs less than 10 pounds and operates seamlessly on an external battery, ensuring that testing can continue uninterrupted during the rolling power blackouts common in many high-burden regions.[2][3]
Operating the system requires minimal specialized training, significantly lowering the barrier for deployment in under-resourced and understaffed clinics. A healthcare worker simply collects the patient's swab, inserts it into the single-use cartridge, and loads it into the automated analyzer.[2][4]
The internal mechanism handles the complex sample preparation, sequence-specific capture, and DNA amplification entirely automatically. Within 20 minutes, the digital display provides a clear, qualitative result indicating the presence or absence of the pathogen, removing the need for expert interpretation.[2][3]
This automated workflow eliminates the risk of cross-contamination that frequently plagues manual bacterial cultures. By keeping the entire amplification process sealed within the disposable cartridge, the system protects both the integrity of the test and the safety of the operator.[2][3]
Shifting the global response
The development of the DASH MTB assay represents the culmination of a long-standing collaboration between Northwestern's Center for Innovation in Global Health Technologies and international partners. Researchers from the University of Washington, the University of Cape Town, and Stellenbosch University contributed heavily to the clinical validation.[2][3]
The technology builds directly on the research team's previous successes in point-of-care diagnostics. The DASH platform was initially deployed to provide rapid testing for COVID-19 and hepatitis C, proving the hardware's durability and viability in real-world clinical settings.[2]
Public health officials have long warned that delayed diagnosis is a primary driver of the global tuberculosis epidemic. When patients are forced to wait weeks for laboratory results, they often drop out of the healthcare system entirely, continuing to transmit the bacteria to their households.[2][5]
A rapid, accurate field test directly addresses this dangerous attrition rate. By confirming the infection immediately, clinicians can dispense the necessary six-month antibiotic regimen before the patient leaves the facility, drastically improving treatment adherence and long-term survival outcomes.[1][2]
The financial implications for patients are equally significant. A single-visit diagnosis eliminates the need for repeated travel to distant medical centers, reducing the catastrophic out-of-pocket costs and lost wages that often prevent impoverished individuals from seeking care.[2][5]
While the initial clinical data is highly promising, the research team acknowledges that broader field testing is necessary. The current validation relied on a relatively small cohort of 110 tongue swab specimens, and performance must be verified across diverse global populations and varying clinical conditions.[3]
Scaling up deployment
The next phase of development will focus heavily on scaling manufacturing capabilities and securing the regulatory approvals required for international use. The researchers are also exploring whether the platform can be adapted to detect drug-resistant strains of the bacteria.[2][3]
Multidrug-resistant tuberculosis remains a critical public health crisis, requiring entirely different, more toxic treatment protocols. A point-of-care test that could simultaneously identify the pathogen and its specific resistance profile would further streamline clinical decision-making in the field.[2][5]
For now, the ability to accurately diagnose the disease without a sputum sample marks a substantial clinical victory. The tongue swab method removes a major physical barrier to testing, expanding diagnostic access to the most vulnerable demographic groups.[1][4]
As global health organizations work desperately to reverse the recent surge in tuberculosis mortality, decentralized diagnostics will play a central role. The DASH system provides a practical, proven blueprint for moving gold-standard testing out of the laboratory and directly into the community.[2][5]
As global health organizations work desperately to reverse the recent surge in tuberculosis mortality, decentralized diagnostics will play a central role.
Key points
- The DASH Rapid PCR System detects Mycobacterium tuberculosis from a tongue swab or sputum sample in just 20 minutes.
- In clinical trials, the portable device matched the accuracy of the current gold-standard molecular test, achieving 100 percent specificity.
- The system operates on external batteries and uses test cartridges that remain stable at 45 degrees Celsius for up to a year.
- Up to one-third of tuberculosis patients cannot produce the deep-lung sputum required for standard diagnostics, making the tongue-swab option a critical advancement.
Open questions
- Whether the DASH system can be adapted to simultaneously detect multidrug-resistant strains of tuberculosis.
- How the tongue swab assay will perform across larger, more diverse global populations outside of the initial South African cohort.
- The final per-unit cost of the device and cartridges when manufactured at a global scale.
- Global Health Researchers
- Advocate for decentralized diagnostics to halt transmission in high-burden countries.
- Public Health Officials
- Emphasize the need for diagnostic tools that do not rely on cold-chain logistics.
- Clinical Practitioners
- Value the shift from sputum to tongue swabs to remove physical barriers to testing.
Perspectives this story doesn't cover
- Health ministry procurement officials who must balance the cost of new diagnostic hardware against existing healthcare budgets.
- Patients in remote areas who struggle with the physical demands of traditional sputum collection.
Sources
[1]Northwestern UniversityGlobal Health ResearchersTuberculosis rapid test allows in-the-field results
Read on Northwestern University →
[2]EurekAlert!Public Health OfficialsTuberculosis rapid test allows in-the-field results
Read on EurekAlert! →
[3]Open Forum Infectious DiseasesGlobal Health ResearchersDevelopment of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System
Read on Open Forum Infectious Diseases →
[4]Mirage NewsPublic Health OfficialsTuberculosis Rapid Test Allows In-the-field Results
Read on Mirage News →
[5]Medical XpressClinical PractitionersTuberculosis rapid test allows in-the-field results
Read on Medical Xpress →
More in Health
See all →Public Health
UN Assessment Warns Endocrine-Disrupting Chemicals in Consumer Goods Pose Escalating Health Crisis
6 sources
Measles Resurgence
US and Mexico Lose Measles Elimination Status Amid Worst Outbreak in Decades
7 sources
Antimicrobial Resistance
WHO Warns Fewer Than One in Five Countries Fund Antimicrobial Resistance Plans
6 sources
Infectious Diseases
Brazil Confirms First Mpox Fatality of 2026 as Cases Climb
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




